Literature DB >> 2917132

Mortality and causes of death in Dutch haemophiliacs, 1973-86.

F R Rosendaal1, I Varekamp, C Smit, A H Bröcker-Vriends, H van Dijck, J P Vandenbroucke, J Hermans, T P Suurmeijer, E Briët.   

Abstract

Mortality figures were calculated for a group of 717 Dutch haemophiliacs over the period 1973-86. Follow-up was on average 10.9 years; no patients were lost to follow-up. The data were compared to the general male population by actuarial methods and patient-year analysis. Forty-three patients died, while 20 deaths were expected in a hypothetical group of non-haemophiliacs of the same age distribution. Hence, overall mortality was 2.1 times higher than in the general population. This leads to a calculated life expectancy of 66 years, as compared to 74 years in the general male population. Mortality did not differ much by severity of haemophilia. A possibly beneficial effect of prophylaxis on longevity was observed. Haemorrhage occurred in half of all deaths and among these traumatic bleeding was the most prevalent. The number of deaths due to ischaemic heart disease was significantly lower (80% reduction) than expected and therefore the authors conclude that haemophilia offers protection against ischaemic heart disease. Cancer mortality was significantly higher (2.5 times) than expected.

Entities:  

Mesh:

Year:  1989        PMID: 2917132     DOI: 10.1111/j.1365-2141.1989.tb06277.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII.

Authors:  Jean Philippe Galanaud; Nathalie Pelletier-Fleury; Hélène Logerot-Lebrun; Thierry Lambert
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  Sex ratio of the mutation frequencies in haemophilia A: coagulation assays and RFLP analysis.

Authors:  A H Bröcker-Vriends; F R Rosendaal; J C van Houwelingen; E Bakker; G J van Ommen; J J van de Kamp; E Briët
Journal:  J Med Genet       Date:  1991-10       Impact factor: 6.318

Review 3.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

4.  Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A.

Authors:  M V Ragni; C G Moore
Journal:  Haemophilia       Date:  2011-03-04       Impact factor: 4.287

5.  Sex ratio of the mutation frequencies in haemophilia A: estimation and meta-analysis.

Authors:  F R Rosendaal; A H Bröcker-Vriends; J C van Houwelingen; C Smit; I Varekamp; H van Dijck; T P Suurmeijer; J P Vandenbroucke; E Briët
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

Review 6.  The contribution of DNA analysis to carrier detection and prenatal diagnosis of hemophilia A and B.

Authors:  A H Bröcker-Vriends; E Bakker; H H Kanhai; G J van Ommen; P H Reitsma; J J van de Kamp; E Briët
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

Review 7.  Management of Hemophilia in Older Patients.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

8.  Factor VIII and coronary heart disease.

Authors:  F R Rosendaal
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

9.  Selective thrombophilia screening of patients with nonarteritic anterior ischemic optic neuropathy.

Authors:  Claudia Kuhli-Hattenbach; Inge Scharrer; Marc Lüchtenberg; Lars-Olof Hattenbach
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-11       Impact factor: 3.117

10.  Determinants of disease and disability in the elderly: the Rotterdam Elderly Study.

Authors:  A Hofman; D E Grobbee; P T de Jong; F A van den Ouweland
Journal:  Eur J Epidemiol       Date:  1991-07       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.